



AA

03C01/023

Attorney's Docket No: M0656/7060

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Ingram and Blanchard
Serial No. : 09/706,574
Filed : November 3, 2000
For : METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY
IN ALZHEIMER'S DISEASE CAUSED BY β -AMYLOID PEPTIDES
Examiner : Unknown
Art Unit : 1623

Certificate of Mailing Under 37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231, on the 4th day of October, 2001.

Monica E. Zombori

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- ☒ [X] Substitute Sequence Listing - Paper Copy w/identical Computer Readable Disk
- ☒ [X] Second Preliminary Amendment
- ☒ [X] Statement Pursuant to 37 CFR 1.821(f) and 37 CFR 1.825 (a) and (b)
- ☒ [X] Copy of Notice to Comply with Requirements for Sequence Disclosures
- ☒ [X] Return Receipt Postcard


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No check is enclosed. If a fee is determined to be required, the balance may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Tel. (617) 720-3500

Docket No.: M0656/7060
Dated: October 4, 2001
X10/05/01



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/706,574	11/03/2000	Vernon M. Ingram	M0656/7060

CONFIRMATION NO. 6165

FORMALITIES LETTER



OC00000006260932

John R. Van Amsterdam
c/o Wolf, Greenfield & Sacks, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, MA 02210-2211

Date Mailed: 07/05/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center
Initial Patent Examination Division (703) 308-1202